Citigroup Inc Avalo Therapeutics, Inc. Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	BUY	$3.0 - $10.45 $165 - $574	55 Added 2.43%	2,321 $1,000
Q1 2022 May 12, 2022	SELL	$7.57 - $21.72 $117,092 - $335,964	-15,468 Reduced 87.22%	2,266 $2,000
Q4 2021 Feb 10, 2022	BUY	$19.68 - $28.68 $230,295 - $335,613	11,702 Added 194.0%	17,734 $30,000
Q3 2021 Nov 10, 2021	BUY	$26.16 - $40.68 $157,797 - $245,381	6,032 New	6,032 $13,000

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $91.6M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.